Abstract #1109
ADC histogram analysis: investigation of treatment response and survival in advanced ovarian cancer
Andrew Nicholas Priest 1 , Andrew J Patterson 1 , Masako Y Kataoka 1 , Ilse Joubert 1 , Mary A McLean 2 , Martin John Graves 1 , Charlotte Hodgkin 2 , Robin A Crawford 3 , Helena M Earl 3 , John R Griffiths 2 , James D Brenton 2,3 , David John Lomas 1 , and Evis Sala 1
1
Radiology, Addenbrooke's Hospital and
University of Cambridge, Cambridge, United Kingdom,
2
Cancer
Research UK Cambridge Institute, Cambridge, United
Kingdom,
3
Oncology and Gynaecological
Oncology, Addenbrooke's Hospital, Cambridge, United
Kingdom
Diffusion-weighted imaging was used to assess treatment
response in advanced ovarian cancer. Histogram analysis
can potentially give more information about
heterogeneous tumours than mean values. This study
investigated, for both primary ovarian tumours and
metastatic disease, how ADC histogram parameters change
with neoadjuvant chemotherapy, and their relationships
to treatment response and survival. Highly significant
changes were found for the primary tumour in responders
but not non-responders, with significantly greater
changes in responders for the mean, 75th and 90th
percentiles. However, no significant differences or
changes were found for metastatic lesions. No
relationship with survival was found for any lesion.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.